$ENLV
Enlivex Therapeutics Ltd. Stock $enlv

$enlv Overview Financials Valuation SEC Filings Company Website

2022 Q4 Form 20-F Financial Statement

#000121390023028398 Filed on April 10, 2023

Income Statement

Concept	2022 Q4	2022	2021 Q4
Revenue	$0.00		$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.145M	$7.104M	$2.648M
YoY Change	-19.0%	10.88%	70.84%
% of Gross Profit
Research & Development	$5.700M	$18.69M	$5.166M
YoY Change	10.34%	51.54%	140.28%
% of Gross Profit
Depreciation & Amortization	$221.0K	$777.0K	$150.0K
YoY Change	47.33%	42.31%	50.0%
% of Gross Profit
Operating Expenses	$7.845M	$25.80M	$7.814M
YoY Change	0.4%	33.75%	111.19%
Operating Profit		-$25.80M
YoY Change		33.75%
Interest Expense	$0.00	-$5.249M
YoY Change		-201.96%
% of Operating Profit
Other Income/Expense, Net	$656.0K	$707.0K	$3.078M
YoY Change	-78.69%	-315.55%
Pretax Income	-$7.189M	-$31.06M	-$4.736M
YoY Change	51.79%	114.68%	-19.18%
Income Tax
% Of Pretax Income
Net Earnings	-$7.189M	-$31.06M	-$4.736M
YoY Change	51.79%	114.68%	-19.18%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.69
Diluted Earnings Per Share	-$0.39	-$1.69	-$258.5K
COMMON SHARES
Basic Shares Outstanding	18.42M shares	18.39M shares
Diluted Shares Outstanding		18.39M shares

Balance Sheet

Concept	2022 Q4	2022	2021 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$50.24M	$50.24M	$84.13M
YoY Change	-40.28%	-40.28%	135.59%
Cash & Equivalents	$49.95M	$47.82M	$10.00M
Short-Term Investments	$299.0K	$299.0K	$72.93M
Other Short-Term Assets	$2.086M	$2.086M	$2.312M
YoY Change	-9.78%	-9.78%	-4.07%
Inventory
Prepaid Expenses	$2.086M		$2.312M
Receivables
Other Receivables	$125.0K
Total Short-Term Assets	$52.33M	$52.33M	$86.44M
YoY Change	-39.46%	-39.46%	126.76%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.875M	$14.90M	$8.219M
YoY Change	20.15%	81.29%	284.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$412.0K	$412.0K	$485.0K
YoY Change	-15.05%	-15.05%	385.0%
Total Long-Term Assets	$15.31M	$15.31M	$8.704M
YoY Change	75.92%	75.92%	288.57%
TOTAL ASSETS
Total Short-Term Assets	$52.33M	$52.33M	$86.44M
Total Long-Term Assets	$15.31M	$15.31M	$8.704M
Total Assets	$67.64M	$67.64M	$95.15M
YoY Change	-28.91%	-28.91%	135.74%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.948M	$1.948M	$878.0K
YoY Change	121.87%	121.87%	90.87%
Accrued Expenses	$4.659M	$4.659M	$3.727M
YoY Change	25.01%	25.01%	36.02%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00
YoY Change
Total Short-Term Liabilities	$6.607M	$6.607M	$4.718M
YoY Change	40.04%	40.04%	7.96%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$4.194M	$4.194M	$5.389M
YoY Change	-22.17%	-22.17%	977.8%
Total Long-Term Liabilities	$4.194M	$4.194M	$5.389M
YoY Change	-22.17%	-22.17%	977.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.607M	$6.607M	$4.718M
Total Long-Term Liabilities	$4.194M	$4.194M	$5.389M
Total Liabilities	$10.80M	$10.80M	$10.11M
YoY Change	6.87%	6.87%	107.54%
SHAREHOLDERS EQUITY
Retained Earnings	-$83.03M		-$51.97M
YoY Change	59.77%
Common Stock	$2.117M		$2.107M
YoY Change	0.47%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$56.84M	$56.84M	$85.04M
YoY Change
Total Liabilities & Shareholders Equity	$67.64M	$67.64M	$95.15M
YoY Change	-28.91%	-28.91%	135.74%

Cashflow Statement

Concept	2022 Q4	2022	2021 Q4
OPERATING ACTIVITIES
Net Income	-$7.189M	-$31.06M	-$4.736M
YoY Change	51.79%	114.68%	-19.18%
Depreciation, Depletion And Amortization	$221.0K	$777.0K	$150.0K
YoY Change	47.33%	42.31%	50.0%
Cash From Operating Activities	-$4.818M	-$23.95M	-$6.591M
YoY Change	-26.9%	36.55%	14.43%
INVESTING ACTIVITIES
Capital Expenditures	$2.581M	$8.122M	-$1.033M
YoY Change	-349.85%	-599.82%	115.21%
Acquisitions
YoY Change
Other Investing Activities	-$295.0K	$70.65M	-$4.313M
YoY Change	-93.16%	-292.06%	8.91%
Cash From Investing Activities	-$2.876M	$62.52M	-$5.346M
YoY Change	-46.2%	-262.79%	20.41%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$3.000K
YoY Change			-100.03%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$150.0K	-3.000K
YoY Change	-100.0%	-99.75%	-100.03%
NET CHANGE
Cash From Operating Activities	-4.818M	-$23.95M	-6.591M
Cash From Investing Activities	-2.876M	$62.52M	-5.346M
Cash From Financing Activities	0.000	$150.0K	-3.000K
Net Change In Cash	-7.694M	$38.72M	-11.94M
YoY Change	-35.56%	669.5%	-3718.18%
FREE CASH FLOW
Cash From Operating Activities	-$4.818M	-$23.95M	-$6.591M
Capital Expenditures	$2.581M	$8.122M	-$1.033M
Free Cash Flow	-$7.399M	-$32.08M	-$5.558M
YoY Change	33.12%	101.51%	5.27%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent		usd
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
CY2022	dei	Document Type DocumentType	20-F
CY2022	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-36578
CY2022	dei	Entity Registrant Name EntityRegistrantName	Enlivex Therapeutics Ltd.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	14 Einstein Street
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Ness Ziona
CY2022	dei	Entity Address Country EntityAddressCountry	IL
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	7403618
CY2022	dei	Security12b Title Security12bTitle	Ordinary Shares, par value of NIS 0.40
CY2022	dei	Trading Symbol TradingSymbol	ENLV
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2022Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	18421852	shares
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2022	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Firm AuditorFirmId	1024
CY2022	dei	Auditor Name AuditorName	Yarel + Partners
CY2022	dei	Auditor Location AuditorLocation	Tel-Aviv, Israel
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49945000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11202000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	299000	usd
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	10004000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	62924000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2086000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2312000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	52330000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	86442000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9875000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2530000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	5437000	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	6174000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	15312000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	8704000	usd
CY2022Q4	us-gaap	Assets Assets	67642000	usd
CY2021Q4	us-gaap	Assets Assets	95146000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1948000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	878000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4659000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3840000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6607000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	4718000	usd
CY2022Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	4194000	usd
CY2021Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	5389000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4194000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5389000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	10801000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	10107000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.4
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.4
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	45000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	45000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18421852	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18421852	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	18331507	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	18331507	shares
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	2117000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2107000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	136648000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	133796000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	1101000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	1101000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-83025000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-51965000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	56841000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	85039000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67642000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	95146000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18693000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12881000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6086000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7104000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6407000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3699000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	25797000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	19288000	usd
CY2020	us-gaap	Operating Expenses OperatingExpenses	9785000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-25797000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-19288000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-9785000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5263000	usd
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	4820000	usd
CY2020	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-2039000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-31060000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14468000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-11824000	usd
CY2021	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	124000	usd
CY2020	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	2277000	usd
CY2021	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	124000	usd
CY2020	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	2277000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-31060000	usd
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14344000	usd
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-9547000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.69
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.81
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.9
CY2022	enlv	Weighted Average Number Of Shares Outstandingin Shares WeightedAverageNumberOfSharesOutstandinginShares	18394886	shares
CY2021	enlv	Weighted Average Number Of Shares Outstandingin Shares WeightedAverageNumberOfSharesOutstandinginShares	17859713	shares
CY2020	enlv	Weighted Average Number Of Shares Outstandingin Shares WeightedAverageNumberOfSharesOutstandinginShares	13169208	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	11282000	usd
CY2020	enlv	Cash Consideration CashConsideration	26968000	usd
CY2020	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	2501000	usd
CY2020	enlv	Shares And Warrants Issued During Period Issuance Of Cash Consideration Of Stock Values SharesAndWarrantsIssuedDuringPeriodIssuanceOfCashConsiderationOfStockValues	24467000	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	101000	usd
CY2020	enlv	Exercise Of Warrants ExerciseOfWarrants	8514000	usd
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	670000	usd
CY2020	enlv	Other Comprehensive Gain OtherComprehensiveGain	2277000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-11824000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	35487000	usd
CY2021	enlv	Cash Consideration CashConsideration	57629000	usd
CY2021	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	4455000	usd
CY2021	enlv	Shares And Warrants Issued During Period Issuance Of Cash Consideration Of Stock Values SharesAndWarrantsIssuedDuringPeriodIssuanceOfCashConsiderationOfStockValues	53174000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	106000	usd
CY2021	enlv	Exercise Of Warrants ExerciseOfWarrants	7702000	usd
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2914000	usd
CY2021	enlv	Other Comprehensive Gain OtherComprehensiveGain	124000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14468000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	85039000	usd
CY2022	us-gaap	Stock Issued During Period Value Stock Options Exercised Net Of Tax Benefit Expense StockIssuedDuringPeriodValueStockOptionsExercisedNetOfTaxBenefitExpense	150000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2712000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-31060000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	56841000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-31060000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-14468000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-11824000	usd
CY2022	us-gaap	Depreciation Depreciation	777000	usd
CY2021	us-gaap	Depreciation Depreciation	546000	usd
CY2020	us-gaap	Depreciation Depreciation	286000	usd
CY2022	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1983000	usd
CY2021	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	5590000	usd
CY2022	enlv	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	831000	usd
CY2021	enlv	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	413000	usd
CY2020	enlv	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	167000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2712000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2914000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	670000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-278000	usd
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1249000	usd
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1823000	usd
CY2022	enlv	Increase Decrease In Accounts Payables Trade IncreaseDecreaseInAccountsPayablesTrade	1168000	usd
CY2021	enlv	Increase Decrease In Accounts Payables Trade IncreaseDecreaseInAccountsPayablesTrade	442000	usd
CY2020	enlv	Increase Decrease In Accounts Payables Trade IncreaseDecreaseInAccountsPayablesTrade	36000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	684000	usd
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-466000	usd
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-2022000	usd
CY2022	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-1326000	usd
CY2021	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-84000	usd
CY2020	us-gaap	Increase Decrease In Operating Liabilities IncreaseDecreaseInOperatingLiabilities	-143000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23953000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17542000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11007000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	8122000	usd
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1625000	usd
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1019000	usd
CY2022	enlv	Investment In Shortterm Bank Deposits InvestmentInShorttermBankDeposits	9705000	usd
CY2021	enlv	Investment In Shortterm Bank Deposits InvestmentInShorttermBankDeposits	20030000	usd
CY2020	enlv	Investment In Shortterm Bank Deposits InvestmentInShorttermBankDeposits	-19958000	usd
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	1608000	usd
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	104417000	usd
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	62549000	usd
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	47604000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	62524000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-38408000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20977000	usd
CY2021	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	53174000	usd
CY2020	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	24467000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	7702000	usd
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	8514000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	150000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	106000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	101000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	150000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	60982000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	33082000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	38721000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	5032000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	1098000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11636000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7012000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5524000	usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-408000	usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	390000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	50357000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11636000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7012000	usd
CY2022	enlv	Cash Received For Interest Net CashReceivedForInterestNet	666000	usd
CY2021	enlv	Cash Received For Interest Net CashReceivedForInterestNet	39000	usd
CY2020	enlv	Cash Received For Interest Net CashReceivedForInterestNet	160000	usd
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.4
CY2022Q4	enlv	Accumulated Deficit AccumulatedDeficit	83200000	usd
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><b><i>Use of estimates</i></b></p><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0in; text-align: justify">The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates, judgments and assumptions, it also requires that management exercise its judgment in applying the Company’s accounting policies. The Company’s management believes that the estimates, judgments and assumptions used were reasonable based upon information available at the time they were made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements, and the reported amounts in the statements of operations during each reporting period. Actual results could differ materially from those estimates.</p><p style="text-indent: 0.5in; font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p>
CY2022	us-gaap	Description Of Difference Between Reported Amount And Reporting Currency Denominated Amount DescriptionOfDifferenceBetweenReportedAmountAndReportingCurrencyDenominatedAmount	NIS 3.519
CY2021	us-gaap	Description Of Difference Between Reported Amount And Reporting Currency Denominated Amount DescriptionOfDifferenceBetweenReportedAmountAndReportingCurrencyDenominatedAmount	NIS 3.110
CY2020	us-gaap	Description Of Difference Between Reported Amount And Reporting Currency Denominated Amount DescriptionOfDifferenceBetweenReportedAmountAndReportingCurrencyDenominatedAmount	NIS 3.215
CY2022	enlv	Increasedecrease During The Years IncreasedecreaseDuringTheYears	0.1315	pure
CY2021	enlv	Increasedecrease During The Years IncreasedecreaseDuringTheYears	-0.0327	pure
CY2020	enlv	Increasedecrease During The Years IncreasedecreaseDuringTheYears	-0.0697	pure
CY2021	enlv	Weighted Average Number Of Stock Options Exercisedin Shares WeightedAverageNumberOfStockOptionsExercisedinShares	16715	shares
CY2020	enlv	Weighted Average Number Of Stock Options Exercisedin Shares WeightedAverageNumberOfStockOptionsExercisedinShares	21749	shares
CY2022	enlv	Net Loss Gain Recognized On Equity Securities NetLossGainRecognizedOnEquitySecurities	-1983000	usd
CY2021	enlv	Net Loss Gain Recognized On Equity Securities NetLossGainRecognizedOnEquitySecurities	5590000	usd
CY2020	enlv	Net Loss Gain Recognized On Equity Securities NetLossGainRecognizedOnEquitySecurities	0	usd
CY2022	enlv	Weighted Average Number Of Restricted Stock Units Vested WeightedAverageNumberOfRestrictedStockUnitsVested	50364	shares
CY2021	enlv	Weighted Average Number Of Warrants Exercised WeightedAverageNumberOfWarrantsExercised	769819	shares
CY2020	enlv	Weighted Average Number Of Warrants Exercised WeightedAverageNumberOfWarrantsExercised	209570	shares
CY2022	enlv	Number Of Shares Used In Per Share Computation NumberOfSharesUsedInPerShareComputation	18394886	shares
CY2021	enlv	Number Of Shares Used In Per Share Computation NumberOfSharesUsedInPerShareComputation	17859713	shares
CY2020	enlv	Number Of Shares Used In Per Share Computation NumberOfSharesUsedInPerShareComputation	13169208	shares
CY2022	enlv	Patents Relatedcosts PatentsRelatedcosts	536000	usd
CY2021	enlv	Patents Relatedcosts PatentsRelatedcosts	373000	usd
CY2020	enlv	Patents Relatedcosts PatentsRelatedcosts	374000	usd
CY2022	enlv	Tax Benefit Percentage TaxBenefitPercentage	0.50	pure
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	705000	usd
CY2022	enlv	Weighted Average Number Of Shares Related To Outstanding Potential Shares Excluded From The Calculations Of Diluted Net Loss Per Share WeightedAverageNumberOfSharesRelatedToOutstandingPotentialSharesExcludedFromTheCalculationsOfDilutedNetLossPerShare	2902423	shares
CY2021	enlv	Weighted Average Number Of Shares Related To Outstanding Potential Shares Excluded From The Calculations Of Diluted Net Loss Per Share WeightedAverageNumberOfSharesRelatedToOutstandingPotentialSharesExcludedFromTheCalculationsOfDilutedNetLossPerShare	2910491	shares
CY2020	enlv	Weighted Average Number Of Shares Related To Outstanding Potential Shares Excluded From The Calculations Of Diluted Net Loss Per Share WeightedAverageNumberOfSharesRelatedToOutstandingPotentialSharesExcludedFromTheCalculationsOfDilutedNetLossPerShare	3526214	shares
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	31060000	usd
CY2021	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	14468000	usd
CY2020	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	11824000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	31060000	usd
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	14468000	usd
CY2020	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	11824000	usd
CY2022	enlv	Number Of Common Shares NumberOfCommonShares	18331507	shares
CY2021	enlv	Number Of Common Shares NumberOfCommonShares	14587934	shares
CY2020	enlv	Number Of Common Shares NumberOfCommonShares	10334126	shares
CY2021	enlv	Weighted Average Number Of Shares Issued For Cash WeightedAverageNumberOfSharesIssuedForCash	2485245	shares
CY2020	enlv	Weighted Average Number Of Shares Issued For Cash WeightedAverageNumberOfSharesIssuedForCash	2603763	shares
CY2022	enlv	Weighted Average Number Of Stock Options Exercisedin Shares WeightedAverageNumberOfStockOptionsExercisedinShares	13015	shares
CY2022	enlv	Basic And Diluted Netloss Per Sharein Dollars Per Share BasicAndDilutedNetlossPerShareinDollarsPerShare	-1.69
CY2021	enlv	Basic And Diluted Netloss Per Sharein Dollars Per Share BasicAndDilutedNetlossPerShareinDollarsPerShare	-0.81
CY2020	enlv	Basic And Diluted Netloss Per Sharein Dollars Per Share BasicAndDilutedNetlossPerShareinDollarsPerShare	-0.9
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0in; text-align: justify"><b><i>Concentrations of credit risk:</i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0in; text-align: justify">The Company’s financial instruments that are exposed to concentrations of credit risk consist primarily of cash and cash equivalents, restricted cash and bank deposits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0in; text-align: justify">Cash and cash equivalents, restricted cash and deposits are invested in major banks in Israel. Such deposits in Israel are not insured. Management believes that the financial institutions that hold the Company’s investments are financially sound and, accordingly, minimal credit risk exists with respect to these investments.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0in; text-align: justify">The Company had no foreign exchange contracts or any other hedging arrangements as of December 31, 2022.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 67.65pt; text-align: justify"> </p>
CY2022	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0in; text-align: justify"><b><i>Reclassification </i></b></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-indent: 0in; text-align: justify">Certain comparative figures have been reclassified to conform to the current year presentation. Such reclassifications did not have any significant impact on the Company’s equity, net income or cash flows.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 49.65pt; text-align: justify"> </p>
CY2022	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.003	pure
CY2021	us-gaap	Short Term Debt Interest Rate Increase ShortTermDebtInterestRateIncrease	0.006	pure
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	299000	usd
CY2022Q4	us-gaap	Cash And Due From Banks CashAndDueFromBanks	2123000	usd
CY2021Q4	us-gaap	Cash And Due From Banks CashAndDueFromBanks	1199000	usd
CY2022Q4	enlv	Annual Average Interest Rates AnnualAverageInterestRates	0.0395	pure
CY2021Q4	enlv	Annual Average Interest Rates AnnualAverageInterestRates	0.001	pure
CY2022Q4	us-gaap	Deposits Deposits	47822000	usd
CY2021Q4	us-gaap	Deposits Deposits	10003000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	49945000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11202000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	113000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	113000	usd
CY2022Q4	us-gaap	Regulated Entity Other Assets Noncurrent RegulatedEntityOtherAssetsNoncurrent	299000	usd
CY2021Q4	us-gaap	Regulated Entity Other Assets Noncurrent RegulatedEntityOtherAssetsNoncurrent	321000	usd
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	50357000	usd
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	11636000	usd
CY2021Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	10004000	usd
CY2021Q3	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2026-09-18
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	1439000	usd
CY2021Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	1112000	usd
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	522000	usd
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	1073000	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	125000	usd
CY2021Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	127000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2086000	usd
CY2021Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2312000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11982000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3860000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2107000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1330000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9875000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2530000	usd
CY2022	us-gaap	Depreciation Depreciation	777000	usd
CY2021	us-gaap	Depreciation Depreciation	546000	usd
CY2020	us-gaap	Depreciation Depreciation	286000	usd
CY2021Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P22M
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	299000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	321000	usd
CY2022Q4	us-gaap	Deposit Assets DepositAssets	8000	usd
CY2021Q4	us-gaap	Deposit Assets DepositAssets	3000	usd
CY2022Q4	enlv	Longterm Prepaid Expense LongtermPrepaidExpense	105000	usd
CY2021Q4	enlv	Longterm Prepaid Expense LongtermPrepaidExpense	161000	usd
CY2022Q4	enlv	Rightof Use Assets Net RightofUseAssetsNet	5025000	usd
CY2021Q4	enlv	Rightof Use Assets Net RightofUseAssetsNet	5689000	usd
CY2022Q4	us-gaap	Other Assets OtherAssets	5437000	usd
CY2021Q4	us-gaap	Other Assets OtherAssets	6174000	usd
CY2019Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P24M
CY2019Q3	us-gaap	Area Of Land AreaOfLand	55	sqm
CY2021Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P24M
CY2018Q3	us-gaap	Area Of Land AreaOfLand	420	sqm
CY2018Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P60M
CY2020Q4	us-gaap	Area Of Land AreaOfLand	421	sqm
CY2020Q4	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P33M
CY2021Q3	us-gaap	Area Of Land AreaOfLand	455	sqm
CY2021Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P63M
CY2021Q3	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2026-10-31
CY2021Q3	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P60M
CY2022	enlv	Lease Agreements Period LeaseAgreementsPeriod	P36M
CY2022	us-gaap	Operating Lease Expense OperatingLeaseExpense	1037000	usd
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	698000	usd
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	243000	usd
CY2022	enlv	Cash Used In Operating Activities CashUsedInOperatingActivities	875000	usd
CY2021	enlv	Cash Used In Operating Activities CashUsedInOperatingActivities	449000	usd
CY2020	enlv	Cash Used In Operating Activities CashUsedInOperatingActivities	223000	usd
CY2022	enlv	Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities	179000	usd
CY2021	enlv	Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities	5446000	usd
CY2020	enlv	Right Of Use Assets Obtained In Exchange For New Operating Lease Liabilities RightOfUseAssetsObtainedInExchangeForNewOperatingLeaseLiabilities	398000	usd
CY2022	enlv	Schedule Of Operating Lease Related Activities ScheduleOfOperatingLeaseRelatedActivities	<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">December 31,</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(in thousands<b>)</b></span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2022</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><span style="font-family: Times New Roman, Times, Serif">2021</span></td><td style="padding-bottom: 1.5pt; font-weight: bold"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom"> <td style="text-indent: -0.125in; padding-left: 0.125in"><span style="font-family: Times New Roman, Times, Serif">Supplemental information related to operating leases, including location of amounts reported in the accompanying consolidated balance sheets, follows:</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td colspan="2"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Other assets - Right-of-Use assets</span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,445</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="width: 9%; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,329</span></td><td style="width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Accumulated amortization</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">1,420</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">640</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Operating lease Right-of-Use assets, net</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,025</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,689</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left"><span style="font-family: Times New Roman, Times, Serif">Lease liabilities – current - Accounts payable and accrued liabilities</span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">653</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="text-align: right"><span style="font-family: Times New Roman, Times, Serif">617</span></td><td style="text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif">Lease liabilities – noncurrent</span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,194</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif">5,389</span></td><td style="padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Total operating lease liabilities</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">4,847</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">6,006</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average remaining lease term in years</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">7.6</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">8.6</span></td><td style="padding-bottom: 4pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td></tr> <tr style="vertical-align: bottom; "> <td style="text-indent: -0.125in; padding-left: 0.125in; padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif">Weighted average annual discount rate</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.4</span></td><td style="padding-bottom: 2pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td><td style="padding-bottom: 4pt"><span style="font-family: Times New Roman, Times, Serif"> </span></td> <td style="border-bottom: Black 4pt double; text-align: left"><span style="font-family: Times New Roman, Times, Serif"> </span></td><td style="border-bottom: Black 4pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif">3.6</span></td><td style="padding-bottom: 2pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif">%</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
CY2022Q4	enlv	Other Assets Rightofuse Assets OtherAssetsRightofuseAssets	6445000	usd
CY2021Q4	enlv	Other Assets Rightofuse Assets OtherAssetsRightofuseAssets	6329000	usd
CY2022Q4	enlv	Accumulated Amortization AccumulatedAmortization	1420000	usd
CY2021Q4	enlv	Accumulated Amortization AccumulatedAmortization	640000	usd
CY2022Q4	enlv	Operating Lease Rightofuse Assets Net OperatingLeaseRightofuseAssetsNet	5025000	usd
CY2021Q4	enlv	Operating Lease Rightofuse Assets Net OperatingLeaseRightofuseAssetsNet	5689000	usd
CY2022Q4	enlv	Accounts Payable And Accrued Liabilities AccountsPayableAndAccruedLiabilities	653000	usd
CY2021Q4	enlv	Accounts Payable And Accrued Liabilities AccountsPayableAndAccruedLiabilities	617000	usd
CY2022Q4	enlv	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	4194000	usd
CY2021Q4	enlv	Lease Liabilities Noncurrent LeaseLiabilitiesNoncurrent	5389000	usd
CY2022Q4	enlv	Total Operating Lease Liabilities TotalOperatingLeaseLiabilities	4847000	usd
CY2021Q4	enlv	Total Operating Lease Liabilities TotalOperatingLeaseLiabilities	6006000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y7M6D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P8Y7M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.034	pure
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.036	pure
CY2020Q1	enlv	Net Proceeds Offering NetProceedsOffering	15238000	usd
CY2020Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	1000000	shares
CY2020Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	8
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	788000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	681000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	703000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	607000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	2752000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5531000	usd
CY2022Q4	enlv	Less Imputed Interest LessImputedInterest	684000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4847000	usd
CY2022	enlv	Royalties In Sales Percentage RoyaltiesInSalesPercentage	1	pure
CY2022Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Contingent Liability BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedContingentLiability	9200000	usd
CY2022Q1	us-gaap	Other General Expense OtherGeneralExpense	4800000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	1000000	usd
CY2021Q2	enlv	Grant Total Amount GrantTotalAmount	1200000	usd
CY2018Q3	enlv	Agreement Description AgreementDescription	Pursuant to the agreement, upon termination of the Chairman’s board service, under certain conditions defined in the agreement, the Executive Chairman will be entitled to receive an amount of up to three times his then annual base retainer plus the value of accrued benefits. As of December 31, 2022, no termination liability was accrued or paid.
CY2021Q4	enlv	Percentage Of Gross Proceeds PercentageOfGrossProceeds	0.0333	pure
CY2021Q4	enlv	Commercial Transaction CommercialTransaction	20000000	usd
CY2022Q4	enlv	Aggregate Offering Price AggregateOfferingPrice	100000000	usd
CY2022Q4	us-gaap	Debt Instrument Redemption Price Percentage DebtInstrumentRedemptionPricePercentage	0.03	pure
CY2022	us-gaap	Partners Capital Account Public Sale Of Units Net Of Offering Costs PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts	137	usd
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2296107	shares
CY2021Q1	enlv	Additional Ordinary Shares AdditionalOrdinaryShares	344416	shares
CY2021Q1	enlv	Public Share PublicShare	20
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2296107	shares
CY2021Q1	enlv	Public Share PublicShare	18.6
CY2021Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	268205	shares
CY2021Q1	enlv	Public Share PublicShare	18.6
CY2021Q1	enlv	Sales Agent Commission Percentage SalesAgentCommissionPercentage	0.07	pure
CY2021Q1	enlv	Gross Proceeds In Percentage GrossProceedsInPercentage	0.01	pure
CY2021Q1	enlv	Warrants To Purchase WarrantsToPurchase	179501	shares
CY2021Q1	us-gaap	Costs And Expenses CostsAndExpenses	126000	usd
CY2021Q1	us-gaap	Partners Capital Account Public Sale Of Units Net Of Offering Costs PartnersCapitalAccountPublicSaleOfUnitsNetOfOfferingCosts	47023000	usd
CY2020Q4	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	476983	shares
CY2020Q4	us-gaap	Sale Leaseback Transaction Gross Proceeds Financing Activities SaleLeasebackTransactionGrossProceedsFinancingActivities	8557000	usd
CY2020Q4	enlv	Average Gross Price Per AverageGrossPricePer	17.94
CY2020Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	2093750	shares
CY2020Q1	us-gaap	Share Price SharePrice	8
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.90
CY2020Q1	enlv	Net Proceeds Offering NetProceedsOffering	7218000	usd
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	704355	shares
CY2021Q4	enlv	Weighted Average Exercises Price Outstanding WeightedAverageExercisesPriceOutstanding	13.18
CY2021Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	1407683	shares
CY2020Q4	enlv	Weighted Average Exercises Price Outstanding WeightedAverageExercisesPriceOutstanding	12.33
CY2021	enlv	Number Of Warrants Issued NumberOfWarrantsIssued	179501	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	25
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	502104	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	9.09
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	27016	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	180
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised	855813	shares
CY2021Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	9
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	202251	shares
CY2022Q4	enlv	Weighted Average Exercises Price Outstanding WeightedAverageExercisesPriceOutstanding	23.31
CY2021Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	704355	shares
CY2021Q4	enlv	Weighted Average Exercises Price Outstanding WeightedAverageExercisesPriceOutstanding	13.18
CY2022Q4	enlv	Number Of Warrants Outstanding NumberOfWarrantsOutstanding	202251	shares
CY2022	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	4150704	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	635594	shares
CY2022	enlv	Expire Grant Year ExpireGrantYear	P10Y
CY2021Q4	enlv	Weighted Average Exercise Prices WeightedAverageExercisePrices	8.69
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	601227	shares
CY2020Q4	enlv	Weighted Average Exercise Prices WeightedAverageExercisePrices	5.93
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	5.49
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.23
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.93
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	529082	shares
CY2021Q4	enlv	Weighted Average Exercise Prices WeightedAverageExercisePrices	8.69
CY2020Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	601227	shares
CY2020Q4	enlv	Weighted Average Exercise Prices WeightedAverageExercisePrices	5.93
CY2019Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	526351	shares
CY2019Q4	enlv	Weighted Average Exercise Prices WeightedAverageExercisePrices	7.03
CY2022	enlv	Sharebased Compensations Arrangement By Sharebased Payment Award Options Granted Number Of Shares SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsGrantedNumberOfShares	860492	shares
CY2022Q4	enlv	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.49
CY2021	enlv	Sharebased Compensations Arrangement By Sharebased Payment Award Options Granted Number Of Shares SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsGrantedNumberOfShares	345500	shares
CY2021Q4	enlv	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.14
CY2020	enlv	Sharebased Compensations Arrangement By Sharebased Payment Award Options Granted Number Of Shares SharebasedCompensationsArrangementBySharebasedPaymentAwardOptionsGrantedNumberOfShares	360500	shares
CY2020Q4	enlv	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.86
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	370839	shares
CY2022Q4	enlv	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice	7.14
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	385798	shares
CY2021Q4	enlv	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice	7.39
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	249965	shares
CY2020Q4	enlv	Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodWeightedAverageExercisePrice	6.07
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	32730	shares
CY2022Q4	enlv	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice	6.43
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	31847	shares
CY2021Q4	enlv	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice	6.75
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	35659	shares
CY2020Q4	enlv	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeited In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeitedInPeriodWeightedAverageExercisePrice	6.24
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	986005	shares
CY2022Q4	enlv	Weighted Average Exercise Prices WeightedAverageExercisePrices	6.46
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares	529082	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y7M9D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2939434	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	880000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1953429	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2022Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	516000	usd
CY2022	enlv	Weighted Average Period weightedAveragePeriod	P1Y1M28D
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	2712000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2914000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	670000	usd
CY2022	enlv	Israeli Corporate Tax Rate IsraeliCorporateTaxRate	0.23	pure
CY2019Q1	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	42000000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	500000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	49945000	usd
CY2022Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	299000	usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.69
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.04	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.07	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.05	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.19	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.30	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.28	pure
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	213000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits	308000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1365000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	746000	usd
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	3486000	usd
CY2021Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	2527000	usd
CY2022Q4	enlv	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets	185000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	23693000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	22444000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	28942000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	26025000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	28942000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	26025000	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	1322000	usd
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	1331000	usd
CY2020	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	522000	usd
CY2022Q4	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	412000	usd
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	50656000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	11202000	usd
CY2021Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	10004000	usd
CY2021Q4	us-gaap	Marketable Securities MarketableSecurities	62924000	usd
CY2021Q4	us-gaap	Other Assets Fair Value Disclosure OtherAssetsFairValueDisclosure	434000	usd
CY2021Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	84564000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	6371000	usd
CY2021Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	5054000	usd
CY2020Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	3183000	usd
CY2022	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	8264000	usd
CY2021	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	4557000	usd
CY2020	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	2438000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2044000	usd
CY2021Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1505000	usd
CY2020Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	612000	usd
CY2022	enlv	Share Based Compensations ShareBasedCompensations	876000	usd
CY2021	enlv	Share Based Compensations ShareBasedCompensations	1210000	usd
CY2020	enlv	Share Based Compensations ShareBasedCompensations	401000	usd
CY2022	enlv	Depreciations Depreciations	740000	usd
CY2021	enlv	Depreciations Depreciations	546000	usd
CY2020	enlv	Depreciations Depreciations	273000	usd
CY2022	enlv	Other Other	1605000	usd
CY2021	enlv	Other Other	1029000	usd
CY2020	enlv	Other Other	394000	usd
CY2022	enlv	Research And Development Expenses Gross ResearchAndDevelopmentExpensesGross	19900000	usd
CY2021	enlv	Research And Development Expenses Gross ResearchAndDevelopmentExpensesGross	13901000	usd
CY2020	enlv	Research And Development Expenses Gross ResearchAndDevelopmentExpensesGross	7301000	usd
CY2022	enlv	Israel Innovation Authority Participation In Research And Development Costs And Royalties Payable IsraelInnovationAuthorityParticipationInResearchAndDevelopmentCostsAndRoyaltiesPayable	1207000	usd
CY2021	enlv	Israel Innovation Authority Participation In Research And Development Costs And Royalties Payable IsraelInnovationAuthorityParticipationInResearchAndDevelopmentCostsAndRoyaltiesPayable	1020000	usd
CY2020	enlv	Israel Innovation Authority Participation In Research And Development Costs And Royalties Payable IsraelInnovationAuthorityParticipationInResearchAndDevelopmentCostsAndRoyaltiesPayable	1215000	usd
CY2022	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	18693000	usd
CY2021	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	12881000	usd
CY2020	us-gaap	Research And Development Expense Software Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseSoftwareExcludingAcquiredInProcessCost	6086000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1289000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1138000	usd
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	737000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	681000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	1168000	usd
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost	862000	usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1294000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1080000	usd
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	995000	usd
CY2022	us-gaap	Utilities Operating Expense Maintenance And Operations UtilitiesOperatingExpenseMaintenanceAndOperations	402000	usd
CY2021	us-gaap	Utilities Operating Expense Maintenance And Operations UtilitiesOperatingExpenseMaintenanceAndOperations	167000	usd
CY2020	us-gaap	Utilities Operating Expense Maintenance And Operations UtilitiesOperatingExpenseMaintenanceAndOperations	97000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	895000	usd
CY2021Q4	us-gaap	Prepaid Insurance PrepaidInsurance	783000	usd
CY2020Q4	us-gaap	Prepaid Insurance PrepaidInsurance	486000	usd
CY2022	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	1836000	usd
CY2021	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	1704000	usd
CY2020	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	269000	usd
CY2022	us-gaap	Other Expenses OtherExpenses	707000	usd
CY2021	us-gaap	Other Expenses OtherExpenses	367000	usd
CY2020	us-gaap	Other Expenses OtherExpenses	253000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7104000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6407000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3699000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	835000	usd
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	120000	usd
CY2020	us-gaap	Investment Income Interest InvestmentIncomeInterest	225000	usd
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-1983000	usd
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	5590000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards	4101000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards	562000	usd
CY2020Q4	us-gaap	Deferred Tax Assets Other Loss Carryforwards DeferredTaxAssetsOtherLossCarryforwards	2258000	usd
CY2022	enlv	Bank Commissions And Other Expenses BankCommissionsAndOtherExpenses	14000	usd
CY2021	enlv	Bank Commissions And Other Expenses BankCommissionsAndOtherExpenses	328000	usd
CY2020	enlv	Bank Commissions And Other Expenses BankCommissionsAndOtherExpenses	6000	usd
CY2022	enlv	Financial Expenses FinancialExpenses	-5263000	usd
CY2021	enlv	Financial Expenses FinancialExpenses	4820000	usd
CY2020	enlv	Financial Expenses FinancialExpenses	-2039000	usd
CY2022Q4	us-gaap	Accrued Salaries Current And Noncurrent AccruedSalariesCurrentAndNoncurrent	410000	usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022	us-gaap	Revenues Revenues		usd
CY2022	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent		usd
CY2020	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss		usd
CY2020	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities		usd
CY2020	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities		usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
CY2022	enlv	Cash Paid For Taxes CashPaidForTaxes		usd
CY2021	enlv	Cash Paid For Taxes CashPaidForTaxes		usd
CY2020	enlv	Cash Paid For Taxes CashPaidForTaxes		usd
CY2022	enlv	Weighted Average Number Of Shares Issued For Cash WeightedAverageNumberOfSharesIssuedForCash		shares
CY2021	enlv	Weighted Average Number Of Restricted Stock Units Vested WeightedAverageNumberOfRestrictedStockUnitsVested		shares
CY2020	enlv	Weighted Average Number Of Restricted Stock Units Vested WeightedAverageNumberOfRestrictedStockUnitsVested		shares
CY2022	enlv	Weighted Average Number Of Warrants Exercised WeightedAverageNumberOfWarrantsExercised		shares
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.81
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.90
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.69
CY2022	enlv	Number Of Warrants Issued NumberOfWarrantsIssued		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised		shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations		pure
CY2021Q4	enlv	Deferred Tax Assets Fixed Assets DeferredTaxAssetsFixedAssets		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001596812

Files In Submission

Name	View Source	Status
0001213900-23-028398-index-headers.html	Edgar Link	pending
0001213900-23-028398-index.html	Edgar Link	pending
0001213900-23-028398.txt	Edgar Link	pending
0001213900-23-028398-xbrl.zip	Edgar Link	pending
enlv-20221231.xsd	Edgar Link	pending
enlv-20221231_cal.xml	Edgar Link	unprocessable
enlv-20221231_lab.xml	Edgar Link	unprocessable
enlv-20221231_def.xml	Edgar Link	unprocessable
ex15-1_001.jpg	Edgar Link	pending
ex15-1_002.jpg	Edgar Link	pending
ex15-1_003.jpg	Edgar Link	pending
f20f2022ex12-1_enlivextherap.htm	Edgar Link	pending
f20f2022ex12-2_enlivextherap.htm	Edgar Link	pending
f20f2022ex13-1_enlivextherap.htm	Edgar Link	pending
f20f2022ex13-2_enlivextherap.htm	Edgar Link	pending
f20f2022ex15-1_enlivextherap.htm	Edgar Link	pending
f20f2022ex8-1_enlivextherap.htm	Edgar Link	pending
f20f2022_enlivextherap.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
fin_002.jpg	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f20f2022_enlivextherap_htm.xml	Edgar Link	completed
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
enlv-20221231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ENLV
Enlivex Therapeutics Ltd. Stock $enlv

2022 Q4 Form 20-F Financial Statement

#000121390023028398 Filed on April 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENLV Enlivex Therapeutics Ltd. Stock $enlv

2022 Q4 Form 20-F Financial Statement

#000121390023028398 Filed on April 10, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ENLV
Enlivex Therapeutics Ltd. Stock $enlv